XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)

被引：0
|
作者：
Ferris, Robert L.
Mehanna, Hisham Mohamed
Schoenfeld, Jonathan Daniel
Tahara, Makoto
Yom, Sue S.
Haddad, Robert I.
Koenig, Andre
Salmio, Satu Maaria
Bajars, Marcis
Le Tourneau, Christophe
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Univ Birmingham, Birmingham, England
[3] Dana Farber Canc Inst, Boston, MA USA
[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[5] UCSF, Med Ctr Mt Zion, San Francisco, CA USA
[6] Dana Farber Canc Inst, Ctr Head & Neck Oncol, Boston, MA USA
[7] Healthcare Business Merck KGaA, Darmstadt, Germany
[8] Healthcare Business Merck KGaA, Darmstadt, Germany
[9] Inst Curie, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS6101
引用
收藏
页数：1
相关论文
共 50 条
  • [1] XRay Vision: A Phase 3 Study of Xevinapant Plus Radiotherapy (RT) for High-risk, Cisplatin-ineligible Patients with Resected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN)
    Ferris, R. L.
    Mehanna, H.
    Schoenfeld, J. D.
    Tahara, M.
    Yom, S. S.
    Haddad, R. I.
    Koenig, A.
    Salmio, S.
    Bajars, M.
    Le Tourneau, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E17 - E18
  • [2] Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design
    Ferris, Robert L.
    Mehanna, Hisham
    Schoenfeld, Jonathan D.
    Tahara, Makoto
    Yom, Sue S.
    Haddad, Robert
    Koenig, Andre
    Witzler, Pauline
    Bajars, Marcis
    Le Tourneau, Christophe
    FUTURE ONCOLOGY, 2024, 20 (12) : 739 - 748
  • [3] Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
    Haddad, Robert I.
    Harrington, Kevin
    Tahara, Makoto
    Szturz, Petr
    Le Tourneau, Christophe
    Salmio, Satu
    Bajars, Marcis
    Lee, Nancy Y.
    CANCER TREATMENT REVIEWS, 2023, 119
  • [4] A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Ferris, R. L.
    Kotsakis, A. P.
    Heron, D. E.
    Kim, S.
    Duvvuri, U.
    Kubicek, G. J.
    Grandis, J. R.
    Johnson, J. T.
    Argiris, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study
    Imai, Chiaki
    Saeki, Hiromi
    Yamamoto, Kohei
    Ichikawa, Ayano
    Arai, Makoto
    Tawada, Akinobu
    Suzuki, Takaaki
    Takiguchi, Yuichi
    Hanazawa, Toyoyuki
    Ishii, Itsuko
    ONCOLOGY LETTERS, 2022, 23 (05)
  • [6] Nivolumab (Nivo) and ipilimumab (Ipi) in combination with radiotherapy (RT) in high-risk patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
    Johnson, Jennifer Maria
    Bar Ad, Voichita
    Lorber, Emily
    Poller, Dawn
    Manukian, Gregor
    Luginbuhl, Adam
    Curry, Joseph M.
    Cognetti, David M.
    Keith, Scott W.
    Axelrod, Rita Susan
    Rodeck, Ulrich
    Harshyne, Larry
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review
    Michelon, Isabella
    Nachtigal, Gilca Costa
    Dacoregio, Maria Inez
    Moraes, Ana Cristina Beitia Kraemer
    Moraes, Mauricio
    Piva, Livia Silva
    da Costa, Catiara Terra
    Lund, Rafael Guerra
    Michelon, Douver
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (08)
  • [8] Physician Perspectives on the Management of Patients with Resected High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Who Are Ineligible to Receive Cisplatin: A Podcast
    Haddad, Robert I.
    Harrington, Kevin
    TARGETED ONCOLOGY, 2024, 19 (06) : 823 - 832
  • [9] Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Herchenhorn, D.
    Dias, F. L.
    Pineda, R. M.
    Fonseca, A. J.
    Bezerra, M.
    Ferreira, C. G.
    Knust, R. E.
    Fontao, K.
    Martins, R. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Herchenhorn, D
    Dias, FL
    Araújo, CM
    Ferreira, CG
    Bezerra, M
    Hermont, P
    Lima, RA
    Porto, AL
    Pereira, CG
    Martins, RG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 523S - 523S
12345